Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 2, 2017
Eiger Announces Abstracts and Presentations at the American Association for the Study of Liver Diseases (AASLD) Meeting
PALO ALTO, Calif., Oct. 2, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., (EIGR) today announced that two abstracts will be presented at the American Association for ...
September 28, 2017
Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
PASADENA, Calif. -- (BUSINESS WIRE) -- Arrowhead Pharmaceuticals Inc. (ARWR) today announced results from studies of ARC-520, a prior-generation RNAi therapeutic candidate against chronic hepatitis B ...
September 28, 2017
Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated data on entrectinib – an investigational, ...
September 28, 2017
Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge
TEL AVIV, Israel, and SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD) and Arcturus Therapeutics, Inc., a privately held biotechnology company developing ...
September 28, 2017
Basilea announces license agreement for antibiotic Zevtera® (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.
Basel, Switzerland, September 28, 2017 - Basilea Pharmaceutica Ltd. (BSLN.SW) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a license agreement with ...
September 28, 2017
Onxeo announces compelling preclinical data in combination for its two innovative compounds, AsiDNA™ and belinostat
PARIS, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a French biotechnology company specializing in the development ...
September 28, 2017
VBL Therapeutics to Present at the Chardan Gene Therapy Conference
TEL AVIV, Israel, Sept. 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
September 28, 2017
CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C
ALACHUA, FL--(Marketwired - September 28, 2017) - CTD Holdings, Inc. (CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease ...
September 28, 2017
Albireo Elects Roger Jeffs to Board of Directors
BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 28, 2017
Achaogen Awarded up to $18 Million Contract by BARDA to Support Development of Orally-Administered Antibacterial Candidate C-Scape
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative ...
September 28, 2017
Rockwell Files Calcitriol Post-Approval Manufacturing Submission with FDA
WIXOM, Mich., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), today provided an update on the commercial launch of Calcitriol, stating that it ...
September 27, 2017
Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer and Restructuring to Prioritize OXi4503 for AML
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment ...
September 27, 2017
Kiadis Pharma Provides Update on the Marketing Authorization Application Process for ATIR101™ in Europe
AMSTERDAM-DUIVENDRECHT, The Netherlands -- Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to ...
September 27, 2017
BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital
HACKENSACK, N.J. and PETACH TIKVAH, Israel, Sept. 27, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative ...
September 27, 2017
DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 27, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the ...
September 27, 2017
Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
ENGLEWOOD CLIFFS, N.J. -- (BUSINESS WIRE) -- Immune Pharmaceuticals, Inc. (IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, ...
September 27, 2017
Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2017
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multidrug-resistant (MDR) gram-negative infections, ...
September 27, 2017
Bellerophon Announces $23 Million Private Placement
WARREN, N.J., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH), a clinical-stage biotherapeutics company, announced today that it has entered into a definitive securities ...
September 27, 2017
AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)
BROOKLYN, N.Y., Sept. 27, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma Inc.(AZRX) (“AzurRx” or the “Company”), today provided an update on the first six treated patients ...
September 26, 2017
TherapeuticsMD Announces Pricing of Common Stock Offering
BOCA RATON, Fla. -- (BUSINESS WIRE) -- TherapeuticsMD, Inc. (NYSE American: TXMD) today announced the pricing of an underwritten public offering of 12.4 million shares of ...
Page 89 of 117